Treatment of chronic hepatitis B (CHB) with lamivudine (3TC) is limited by development of drug-resistant mutants at the YMDD motif. We aimed to validate the use of mass spectrometry to detect YMDD mutants and quantify viral subpopulations.
Methods
A total of 21 Chinese patients with severe acute exacerbation of CHB treated with 3TC were studied. Serial serum samples were tested for wild-type and YMDD mutants using matrix assisted laser desorption/ionization time-of-flight mass spectrometry. INNO-LiPA assay was performed for comparison.
Results
At a median follow-up of 192 weeks, 11 patients developed YMDD mutants (six had YIDD, four had YVDD and one had YV/IDD). Mass spectrometry was concordant with INNO-LiPA in all but one patient, in which INNO-LiPA detected coexistence of YIDD and YVDD but mass spectrometry and direct sequencing detected YVDD only. Mass spectrometry was able to reliably detect a minor hepatitis B virus (HBV) subtype at 5% or above. By serial quantitative measurement, several patterns of viral dynamics were observed. In some cases, YMDD mutants dominated the whole viral population. In other cases, the proportion of YMDD mutants fluctuated with time. When more than one mutant was present (that is, YIDD and YVDD), the different mutants might dominate during different time periods.
Conclusions
Mass spectrometry is an accurate and cheap method for the detection of YMDD mutants, even in the presence of overwhelming wild-type HBV. We observed some intriguing mutant viral dynamics during 3TC treatment. Further studies are needed to clarify whether they have any clinical significance.
References
1.
LaiC.L., ChienR.N., LeungN.W.A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.N Engl J Med1998; 339: 61–68.
2.
ChanH.L., HuiA.Y., WongV.W., ChimA.M., WongM.L., SungJ.J.Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.Hepatology2005; 41: 1357–1364.
3.
SongB.C., SuhD.J., LeeH.C., ChungY.H., LeeY.S.Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.Hepatology2000; 32: 803–806.
4.
ChanH.L., LeungN.W., HuiA.Y.A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.Ann Intern Med2005; 142: 240–250.
5.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med2005; 352: 2682–2695.
6.
LokA.S., LaiC.L., LeungN.Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Gastroenterology2003; 125: 1714–1722.
7.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.N Engl J Med2005; 352: 2673–2681.
8.
LaiC.L., GaneE., LiawY.F.Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial.Hepatology2005; 42 (Suppl 1): 748A.
9.
TenneyD.J., LangleyD.R., OiverA.J.Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase.Hepatology2004; 40 (Suppl 1): 245A.
10.
ThabutD., RatziuV., Bernard-ChabertB., PoynardT., BenhamouY., ThibaultV.Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.Gut2003; 52: 614.
11.
FungS.K., ChaeH.B., FontanaR.J.Virologic response and resistance to adefovir in patients with chronic hepatitis B.J Hepatol2006; 44: 283–290.
12.
LokA.S., ZoulimF., LocarniniS.Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.J Clin Microbiol2002; 40: 3729–3734.
13.
SyvanenA.C., Aalto-SetalaK., HarjuL., KontulaK., SoderlundH.A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E.Genomics1990; 8: 684–692.
14.
MohlkeK.L., ErdosM.R., ScottL.J.High-throughput screening for evidence of association by using mass spectrometry genotyping on DNA pools.Proc Natl Acad Sci USA2002; 99: 16928–16933.
15.
BansalA., van den BoomD., KammererS.Association testing by DNA pooling: an effective initial screen.Proc Natl Acad Sci USA2002; 99: 16871–16874.
DingC., MaierE., RoscherA.A., BraunA., CantorC.R.Simultaneous quantitative and allele-specific expression analysis with real competitive PCR.BMC Genet2004; 5: 8.
18.
LoweC.A., DiggleM.A., ClarkeS.C.A single nucleotide polymorphism identification assay for the genotypic characterisation of Neisseria meningitidis using MALDI-TOF mass spectrometry.Br J Biomed Sci2004; 61: 8–10.
19.
MarksF., MeyerC.G., SievertsenJ.Genotyping of Plasmodium falciparum pyrimethamine resistance by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry.Antimicrob Agents Chemother2004; 48: 466–472.
20.
LiuJ., LimS.L., RuanY.SARS transmission pattern in Singapore reassessed by viral sequence variation analysis.PLoS Med2005; 2: e43.
21.
AmexisG., OethP., AbelK.Quantitative mutant analysis of viral quasispecies by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.Proc Natl Acad Sci USA2001; 98: 12097–12102.
22.
ChanH.L., TsangS.W., HuiY., LeungN.W., ChanF.K., SungJ.J.The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.J Viral Hepat2002; 9: 424–428.
23.
LoebK.R., JeromeK.R., GoddardJ.High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system.Hepatology2000; 32: 626–629.
24.
ChanH.L., ChuiA.K., LauW.Y.Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.J Med Virol2002; 68: 182–187.
25.
ChayamaK., SuzukiY., KobayashiM.Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.Hepatology1998; 27: 1711–1716.
MelegariM., ScaglioniP.P., WandsJ.R.Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.Hepatology1998; 27: 628–633.
28.
KimH.S., HanK.H., AhnS.H.Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization.Antivir Ther2005; 10: 441–449.
29.
AberleS.W., KletzmayrJ., WatschingerB.Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.J Clin Microbiol2001; 39: 1972–1974.
30.
HussainM., ChuC.J., SablonE., LokA.S.Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants.J Clin Microbiol2003; 41: 3699–3705.
31.
Cameron-WilsonC.L., MuirP., BallardA.L.Evaluation of a line probe assay for identification of hepatitis B virus precore variants in serum from chronic hepatitis B carriers.J Virol Methods2003; 114: 97–103.
32.
OsiowyC., GilesE.Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype.J Clin Microbiol2003; 41: 5473–5477.
33.
Roque-AfonsoA.M., FereyM.P., MackiewiczV., FkiL., DussaixE.Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.Antivir Ther2003; 8: 627–634.
34.
SertozR.Y., ErensoyS., PasS.Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B.J Chemother2005; 17: 514–520.
